Food and Drug Administration (FDA)
NEWS
Selecta Biosciences is moving forward with development efforts for its gene therapy program for methylmalonic acidemia after the FDA lifted the hold on its clinical trial on March 9.
AbbVie announced Qulipta hit the mark in its Phase III study by reducing mean monthly migraine days compared to placebo. Learn more about this migraine treatment here.
Venatorx Pharmaceuticals shared that its Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.
At the Brigham and Women’s Hospital, a male patient with Secondary Progressive Multiple Sclerosis serves as a beacon of hope for those afflicted with the same neurodegenerative disease.
Two months after he received a gene-edited pig heart, David Bennett Sr. has died. He was 57.
The XTEND-1 study showed that efanesoctocog alfa met its primary endpoint of clinically meaningful bleed prevention in people ages 12 years and older with severe hemophilia.
From artificial intelligence breakthroughs to at-home genetic testing, here are some ways COVID-19 has changed the biopharma industry and what we may see in the near future.
The FDA clinical hold comes after Alpine reported a patient died during the NEON-2 trial.
BMS and Opdivo’s blockbuster checkpoint inhibitor picked up a new regulatory win after the FDA approved the cancer drug in combination with platinum-doublet chemotherapy.
JOBS
IN THE PRESS